Viracta Therapeutics, Inc. VIRX

RBC Capital Sticks to Their Buy Rating for Viracta Therapeutics (VIRX)
RBC Capital Sticks to Their Buy Rating for Viracta Therapeutics (VIRX)
RBC Capital analyst Gregory Renza maintained a Buy rating on Viracta Therapeutics (VIRX – Research Report) yesterday and set a price target of $7.00. The company’s shares closed yesterday at $1.41.

According to TipRanks, Renza is a 4-star analyst with an average return of 8.7% and a 43.93% success rate. Renza covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, ACADIA Pharmaceuticals, and Verastem.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viracta Therapeutics with a $9.25 average price target, a 556.03% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.

See the top stocks recommended by analysts >>

VIRX market cap is currently $54.16M and has a P/E ratio of -1.02.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.

Read More on VIRX:

Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Viracta Therapeutics announces publication of study of Nana-val
Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma
Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medi

SAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that additional data from the Phase 1b/2 clinical trial of Nana-val (nanatinostat in combination with valganciclovir) in patients with recurrent or metastatic (R/M) Epstein-Barr virus-positive (EBV+) nasopharyngeal carcinoma (NPC) showed two ongoing confirmed partial responses (PRs) at higher dose levels. These data were featured in an oral presentation made by A. Dimitrios Colevas, M.D., Professor of Medicine (Oncology) at the Stanford Cancer Institute, during the European Society for Medical Oncology (ESMO) Asia Congress being held in Singapore. Nana-val is the company's all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers.

RBC Cuts Price Target on Viracta Therapeutics to $6 From $7, Keeps Outperform, Speculative Risk
MT Newswires
·
11/10 07:54
1min
Viracta Therapeutics(VIRX.US)
0.466
0.523
-4.74%
+12.17%

RBC Cuts Price Target on Viracta Therapeutics to $6 From $7, Keeps Outperform, Speculative Risk
Disclaimer

523
-4.74%
+12.17%

$VIRACTA Therapeutics(VIRX.US)$ Officer Rothera Mark purchased 100K shares of Common Stocks on Nov 30, Dec 1, 2023 at an average price of $0.4936 for a total value of $49,361.68.

1701729190358411634.png